Your browser doesn't support javascript.
loading
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C.
Almhanna, Khaldoun; Wright, David; Mercade, Teresa Macarulla; Van Laethem, Jean-Luc; Gracian, Antonio Cubillo; Guillen-Ponce, Carmen; Faris, Jason; Lopez, Carolina Muriel; Hubner, Richard A; Bendell, Johanna; Bols, Alain; Feliu, Jaime; Starling, Naureen; Enzinger, Peter; Mahalingham, Devalingham; Messersmith, Wells; Yang, Huyuan; Fasanmade, Adedigbo; Danaee, Hadi; Kalebic, Thea.
Afiliación
  • Almhanna K; Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA. Khaldoun.Almhanna@moffitt.org.
  • Wright D; Florida Cancer Specialists, Tampa, FL, USA.
  • Mercade TM; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Van Laethem JL; Erasme University Hospital, Brussels, Belgium.
  • Gracian AC; HM Universitario Sanchinarro, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
  • Guillen-Ponce C; Departamento de Ciencias Médicas Clínicas, Universidad San Pablo CEU, Madrid, Spain.
  • Faris J; Ramón y Cajal University Hospital, Madrid, Spain.
  • Lopez CM; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
  • Hubner RA; Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Bendell J; The Christie NHS Foundation Trust, Manchester, UK.
  • Bols A; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Feliu J; Brugge Oostende Oncologisch Centrum, Bruges, Belgium.
  • Starling N; CIBERONC, La Paz University Hospital, Madrid, Spain.
  • Enzinger P; The Royal Marsden NHS Foundation Trust, London, UK.
  • Mahalingham D; Dana Farber Cancer Institute, Boston, MA, USA.
  • Messersmith W; University of Texas Health Science Center, San Antonio, TX, USA.
  • Yang H; University of Colorado, Aurora, CO, USA.
  • Fasanmade A; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Danaee H; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
  • Kalebic T; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Invest New Drugs ; 35(5): 634-641, 2017 10.
Article en En | MEDLINE | ID: mdl-28527133
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Inmunoconjugados / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Inmunoconjugados / Anticuerpos Monoclonales / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Invest New Drugs Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos